COLO-B 📈 Coloplast - Overview

Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0060448595

COLO-B: Ostomy, Catheters, Wound, Skin, Urology, Voice, Respiratory

Coloplast A/S is a Danish company that specializes in developing and selling intimate healthcare products and services globally. With a presence in Denmark, the United States, the United Kingdom, France, and other countries, the company operates through five distinct segments: Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care.

In the ostomy care segment, Coloplast offers a range of products designed to improve the quality of life for individuals with ostomies. The SenSura Mio line provides customized fit and discretion for different types of ostomies, while the SenSura Ostomy care solutions and Brava brand accessories cater to various ostomy needs. Additionally, the company's continence care products, such as Conveen Active urine bags, SpeediCath catheters, and Peristeen Plus transanal irrigation system, aim to promote independence and confidence for individuals with continence issues.

The company's wound care portfolio includes conforming dressings under the Biatain Silicone brand and hydrocolloid dressings under the Comfeel brand. Its skin care products range from cleansers and moisturizers to skin protectants, antifungal products, and hand cleansers, as well as InterDry, a solution for skin fold management. These products are designed to promote wound healing, prevent skin breakdown, and maintain skin health.

In the area of interventional urology, Coloplast develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. The company's voice and respiratory care solutions include laryngectomy care products, such as Provox voice prostheses, HMEs, adhesives, and laryngectomy tubes, as well as tracheostomy care products under the Tracoe brand.

Founded in 1954, Coloplast A/S is headquartered in Humlebæk, Denmark, and has established itself as a leader in the intimate healthcare industry. The company's commitment to innovation, quality, and patient-centric solutions has enabled it to make a positive impact on the lives of millions of people worldwide.

For more information, please visit Coloplast's website at https://www.coloplast.com.

Additional Sources for COLO-B Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

COLO-B Stock Overview

Market Cap in USD 28,214m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception

COLO-B Stock Ratings

Growth 5y 6.29%
Fundamental 59.5%
Dividend 50.8%
Rel. Performance Sector 0.77
Analysts -
Fair Price Momentum 845.83 DKK
Fair Price DCF 183.68 DKK

COLO-B Dividends

Dividend Yield 12m 2.92%
Yield on Cost 5y 3.60%
Annual Growth 5y 4.32%
Payout Consistency 99.86%

COLO-B Growth Ratios

Growth Correlation 3m -7.6%
Growth Correlation 12m 44.5%
Growth Correlation 5y -30.3%
CAGR 5y 4.25%
CAGR/Mean DD 5y 0.23
Sharpe Ratio 12m 0.59
Alpha 0.40
Beta 0.42
Volatility 23.43%
Current Volume 144.1k
Average Volume 20d 194.2k
What is the price of COLO-B stocks?
As of December 04, 2024, the stock is trading at DKK 889.60 with a total of 144,090 shares traded.
Over the past week, the price has changed by +3.02%, over one month by +1.18%, over three months by -1.80% and over the past year by +15.89%.
Is Coloplast a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Coloplast (CO:COLO-B) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 59.46 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COLO-B as of December 2024 is 845.83. This means that COLO-B is currently overvalued and has a potential downside of -4.92%.
Is COLO-B a buy, sell or hold?
Coloplast has no consensus analysts rating.
What are the forecast for COLO-B stock price target?
According to ValueRays Forecast Model, COLO-B Coloplast will be worth about 919.1 in December 2025. The stock is currently trading at 889.60. This means that the stock has a potential upside of +3.31%.
Issuer Forecast Upside
Wallstreet Target Price 924.7 3.9%
Analysts Target Price - -
ValueRay Target Price 919.1 3.3%